Health Condition 1: E756- Lipid storage disorder, unspecified
Conditions
Interventions
Intervention1: Group A: Arq Biranjasif and Qurs Afsanteen: Qurs Afsateen is an Unani pharmacopeial formulation which will be given to patients in tablet form orally, with a dose of two tablets twice d
Sponsors
Cental Council for Research in Unani Medicine
Ministry of Ayush
Eligibility
Inclusion criteria
Inclusion criteria: Patients of both genders, diagnosed with Grade I or Grade II non-alcoholic fatty liver disease on ultrasonography, having mild to moderate elevation of liver enzymes (ALT and AST), and with a body mass index between 25 and 35 kg/m will be included in the study.
Exclusion criteria
Exclusion criteria: Patients having severe somatic diseases such as serious respiratory, circulatory, or endocrine disorders, hepatic or renal insufficiency, hepatitis B or C or any other chronic liver disease, those with a history of drug or alcohol abuse, patients on long-term corticosteroid therapy or hepatotoxic drugs, pregnant or lactating women, and patients with cirrhosis, malignancy, or autoimmune hepatitis will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To evaluate and compare the effectiveness of Unani therapeutic modalities Ilaj bil Dawa (Pharmaco Therapy), Ilaj bil Ghiza (Dietotherapy), and Riyazat (Exercise) in combination with each other, versus standard allopathic treatment in improving hepatic steatosis and liver function in patients with NAFLD. Timepoint: baseline and after completion of study i.e.8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To explore correlations between traditional Unani diagnostic concepts (e.g., Mizaj, Balgham predominance) and clinical/laboratory outcomes in NAFLD patients. 2. To determine the safety and tolerability of Unani interventions compared to standard therapy by monitoring adverse events and treatment adherence. 3. To assess the impact of Unani treatments and allopathic therapy on metabolic parameters such as BMI, FBS, Lipid profile, Insulin level 4. To develop Standard Operating Procedures (SOPs) for the implementation of Riyazat Timepoint: Before and after the eight-week clinical trial | — |
Countries
India
Contacts
Public ContactDr Suheena Khanday
Regional research institute of unani medicine Srinagar
Outcome results
None listed